Comparing the current results to its competitors, Teva Pharmaceutical Industries Limited reported Revenue decrease in the 2 quarter 2026 year on year by -0.81 %, despite the revenue increase by the most of its competitors of 12.68 %, recorded in the same quarter.
Teva Pharmaceutical Industries Limited, slower than the average decrease reported by the company's competitors of -6.49 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -6.49 %
Teva Pharmaceutical Industries Limited's Comment on Competition and Industry Peers
UZEDY competes with multiple products in the treatment of multiple sclerosis (MS) in the United States and Europe, including COPAXONE (glatiramer acetate injection), whose market share declined in 2025 due to new treatments. BENDEKA, a liquid infusion formulation of bendamustine hydrochloride licensed from Eagle, faces direct competition from Belrapzo, a ready-to-dilute bendamustine hydrochloride product from Eagle, and Vivimusta, a bendamustine hydrochloride injection from Azurity Pharmaceuticals. Additional competitors to BENDEKA include combination therapies for non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as newer targeted oral therapies. The generic pharmaceutical market is competitive, with increased FDA approvals for generic products contributing to price competition and margin pressures. In Europe, competition is intense regarding pricing, quality, customer service, and portfolio relevance. The company maintains a pan-European presence, whereas most European competitors focus on limited markets or business lines. In international markets, competition includes local generic companies competing on pricing, time to market, reputation, and customer service. The biosimilars business is also highly competitive as intellectual property protections expire in the United States. Competitors identified include Azurity Pharmaceuticals, COPAXONE, and Eagle.
October 3, 2024
In a significant move that underscores the ever-evolving landscape of cancer treatment, Teva Pharmaceuticals International GmbH and mAbxience have announced an expanded strategic partnership with a new global licensing agreement aimed at developing an innovative anti PD-1 oncology biosimilar candidate. This exciting collaboration builds upon the companies’ initial partnership formed in April 2024, epitomizing a commitment to enhancing patient access to vital therapies in the oncology space.The agreement represents a pivotal shift in the biosimilars market, where the demand for effective and accessible cancer therapies continues to grow. As one of the primary therapeutic options for treating various cancers...
Publicly Traded Peers of Teva Pharmaceutical Industries Limited
Sonoma Pharmaceuticals Inc Share Performance
-2.31%
Over The Past 5 Days
Sonoma Pharmaceuticals Inc
Profile
Sonoma Pharmaceuticals Inc operates as a healthcare company that specializes in developing and manufacturing innovative products for various dermatological conditions. They focus on commercializing and distributing advanced solutions for wound care, dermatoses, and other skin disorders, aiming to provide effective treatment options to patients and healthcare professionals.
Palatin Technologies Inc has a business model focused on developing and commercializing innovative medicines in the field of reproductive healthcare and sexual dysfunction. The company's revenue streams primarily come from partnerships, licensing agreements, and product sales.
Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.
Provectus Biopharmaceuticals Inc's business model involves the development and commercialization of innovative therapies in the biopharmaceutical industry.
Sources:
Teva Pharmaceutical Industries Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Teva Pharmaceutical Industries Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
